91.93 USD
-0.58 (-0.63%)
92.56 USD
+0.63 (+0.69%)
We assign a fundamental rating of 6 out of 10 to AZN. AZN was compared to 191 industry peers in the Pharmaceuticals industry. While AZN has a great profitability rating, there are some minor concerns on its financial health. AZN has a correct valuation and a medium growth rate. AZN also has an excellent dividend rating.
1. Profitability
1.1 Basic Checks
In the past year AZN was profitable.
In the past year AZN had a positive cash flow from operations.
In the past 5 years AZN has always been profitable.
AZN had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
The Return On Assets of AZN (8.21%) is better than 89.53% of its industry peers.
AZN has a Return On Equity of 20.48%. This is amongst the best in the industry. AZN outperforms 90.58% of its industry peers.
AZN has a Return On Invested Capital of 14.42%. This is amongst the best in the industry. AZN outperforms 93.72% of its industry peers.
The Average Return On Invested Capital over the past 3 years for AZN is in line with the industry average of 12.85%.
The 3 year average ROIC (11.62%) for AZN is below the current ROIC(14.42%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.21% | ||
| ROE | 20.48% | ||
| ROIC | 14.42% |
ROA(3y)5.35%
ROA(5y)4.19%
ROE(3y)13.78%
ROE(5y)12.42%
ROIC(3y)11.62%
ROIC(5y)9.52%
1.3 Margins
Looking at the Profit Margin, with a value of 16.17%, AZN belongs to the top of the industry, outperforming 88.48% of the companies in the same industry.
AZN's Profit Margin has improved in the last couple of years.
AZN's Operating Margin of 24.34% is amongst the best of the industry. AZN outperforms 91.10% of its industry peers.
AZN's Operating Margin has improved in the last couple of years.
With an excellent Gross Margin value of 81.90%, AZN belongs to the best of the industry, outperforming 85.34% of the companies in the same industry.
In the last couple of years the Gross Margin of AZN has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 24.34% | ||
| PM (TTM) | 16.17% | ||
| GM | 81.9% |
OM growth 3Y21.43%
OM growth 5Y8.6%
PM growth 3Y251.6%
PM growth 5Y18.9%
GM growth 3Y3.31%
GM growth 5Y0.47%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), AZN is creating some value.
AZN has about the same amout of shares outstanding than it did 1 year ago.
Compared to 5 years ago, AZN has more shares outstanding
AZN has a worse debt/assets ratio than last year.
2.2 Solvency
AZN has an Altman-Z score of 3.49. This indicates that AZN is financially healthy and has little risk of bankruptcy at the moment.
With a decent Altman-Z score value of 3.49, AZN is doing good in the industry, outperforming 69.11% of the companies in the same industry.
AZN has a debt to FCF ratio of 3.41. This is a good value and a sign of high solvency as AZN would need 3.41 years to pay back of all of its debts.
AZN has a Debt to FCF ratio of 3.41. This is amongst the best in the industry. AZN outperforms 86.91% of its industry peers.
A Debt/Equity ratio of 0.61 indicates that AZN is somewhat dependend on debt financing.
AZN's Debt to Equity ratio of 0.61 is on the low side compared to the rest of the industry. AZN is outperformed by 68.06% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.61 | ||
| Debt/FCF | 3.41 | ||
| Altman-Z | 3.49 |
ROIC/WACC1.64
WACC8.8%
2.3 Liquidity
AZN has a Current Ratio of 0.88. This is a bad value and indicates that AZN is not financially healthy enough and could expect problems in meeting its short term obligations.
AZN has a worse Current ratio (0.88) than 87.43% of its industry peers.
AZN has a Quick Ratio of 0.88. This is a bad value and indicates that AZN is not financially healthy enough and could expect problems in meeting its short term obligations.
AZN has a worse Quick ratio (0.69) than 86.39% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.88 | ||
| Quick Ratio | 0.69 |
3. Growth
3.1 Past
AZN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 20.61%, which is quite impressive.
AZN shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 18.59% yearly.
AZN shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 13.52%.
The Revenue has been growing by 17.27% on average over the past years. This is quite good.
EPS 1Y (TTM)20.61%
EPS 3Y15.85%
EPS 5Y18.59%
EPS Q2Q%14.42%
Revenue 1Y (TTM)13.52%
Revenue growth 3Y13.06%
Revenue growth 5Y17.27%
Sales Q2Q%11.99%
3.2 Future
Based on estimates for the next years, AZN will show a quite strong growth in Earnings Per Share. The EPS will grow by 12.45% on average per year.
The Revenue is expected to grow by 7.17% on average over the next years.
EPS Next Y11.95%
EPS Next 2Y12.55%
EPS Next 3Y12.2%
EPS Next 5Y12.45%
Revenue Next Year10.2%
Revenue Next 2Y8.11%
Revenue Next 3Y7.34%
Revenue Next 5Y7.17%
3.3 Evolution
Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 19.98, the valuation of AZN can be described as rather expensive.
Based on the Price/Earnings ratio, AZN is valued cheaply inside the industry as 80.63% of the companies are valued more expensively.
AZN's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 26.51.
AZN is valuated rather expensively with a Price/Forward Earnings ratio of 17.56.
Based on the Price/Forward Earnings ratio, AZN is valued a bit cheaper than the industry average as 79.06% of the companies are valued more expensively.
AZN's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 23.13.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 19.98 | ||
| Fwd PE | 17.56 |
4.2 Price Multiples
82.20% of the companies in the same industry are more expensive than AZN, based on the Enterprise Value to EBITDA ratio.
AZN's Price/Free Cash Flow ratio is rather cheap when compared to the industry. AZN is cheaper than 80.63% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 29.79 | ||
| EV/EBITDA | 14.86 |
4.3 Compensation for Growth
AZN's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
AZN has an outstanding profitability rating, which may justify a higher PE ratio.
AZN's earnings are expected to grow with 12.20% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.67
PEG (5Y)1.07
EPS Next 2Y12.55%
EPS Next 3Y12.2%
5. Dividend
5.1 Amount
With a Yearly Dividend Yield of 1.63%, AZN has a reasonable but not impressive dividend return.
AZN's Dividend Yield is rather good when compared to the industry average which is at 0.61. AZN pays more dividend than 92.15% of the companies in the same industry.
AZN's Dividend Yield is comparable with the S&P500 average which is at 2.00.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.63% |
5.2 History
The dividend of AZN has a limited annual growth rate of 1.40%.
AZN has paid a dividend for at least 10 years, which is a reliable track record.
AZN has not decreased its dividend for at least 10 years, so it has a reliable track record of non decreasing dividend.
Dividend Growth(5Y)1.4%
Div Incr Years1
Div Non Decr Years11
5.3 Sustainability
AZN pays out 52.89% of its income as dividend. This is a bit on the high side, but may be sustainable.
The dividend of AZN is growing, but earnings are growing more, so the dividend growth is sustainable.
DP52.89%
EPS Next 2Y12.55%
EPS Next 3Y12.2%
91.93
-0.58 (-0.63%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners48.98%
Inst Owner Change11.46%
Ins Owners0.04%
Ins Owner ChangeN/A
Market Cap285.03B
Revenue(TTM)58.13B
Net Income(TTM)9.40B
Analysts82.42
Price Target97.35 (5.9%)
Short Float %0.28%
Short Ratio1.67
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.63% |
Yearly Dividend2.99
Dividend Growth(5Y)1.4%
DP52.89%
Div Incr Years1
Div Non Decr Years11
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.14%
Min EPS beat(2)-1.74%
Max EPS beat(2)1.47%
EPS beat(4)2
Avg EPS beat(4)2.1%
Min EPS beat(4)-1.74%
Max EPS beat(4)9.32%
EPS beat(8)4
Avg EPS beat(8)0.88%
EPS beat(12)8
Avg EPS beat(12)2.53%
EPS beat(16)12
Avg EPS beat(16)3.75%
Revenue beat(2)0
Avg Revenue beat(2)-0.25%
Min Revenue beat(2)-0.26%
Max Revenue beat(2)-0.24%
Revenue beat(4)1
Avg Revenue beat(4)-0.45%
Min Revenue beat(4)-3.99%
Max Revenue beat(4)2.7%
Revenue beat(8)3
Avg Revenue beat(8)0.07%
Revenue beat(12)4
Avg Revenue beat(12)-0.52%
Revenue beat(16)6
Avg Revenue beat(16)0.18%
PT rev (1m)4.58%
PT rev (3m)4.64%
EPS NQ rev (1m)0.78%
EPS NQ rev (3m)-1.95%
EPS NY rev (1m)-1.62%
EPS NY rev (3m)-1.45%
Revenue NQ rev (1m)-0.29%
Revenue NQ rev (3m)-0.24%
Revenue NY rev (1m)0.57%
Revenue NY rev (3m)0.48%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 19.98 | ||
| Fwd PE | 17.56 | ||
| P/S | 4.9 | ||
| P/FCF | 29.79 | ||
| P/OCF | 18.83 | ||
| P/B | 6.21 | ||
| P/tB | N/A | ||
| EV/EBITDA | 14.86 |
EPS(TTM)4.6
EY5%
EPS(NY)5.24
Fwd EY5.7%
FCF(TTM)3.09
FCFY3.36%
OCF(TTM)4.88
OCFY5.31%
SpS18.75
BVpS14.8
TBVpS-4.36
PEG (NY)1.67
PEG (5Y)1.07
Graham Number39.14
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.21% | ||
| ROE | 20.48% | ||
| ROCE | 17.6% | ||
| ROIC | 14.42% | ||
| ROICexc | 16.02% | ||
| ROICexgc | 81.56% | ||
| OM | 24.34% | ||
| PM (TTM) | 16.17% | ||
| GM | 81.9% | ||
| FCFM | 16.46% |
ROA(3y)5.35%
ROA(5y)4.19%
ROE(3y)13.78%
ROE(5y)12.42%
ROIC(3y)11.62%
ROIC(5y)9.52%
ROICexc(3y)12.66%
ROICexc(5y)10.55%
ROICexgc(3y)112.76%
ROICexgc(5y)85.06%
ROCE(3y)13.95%
ROCE(5y)11.45%
ROICexgc growth 3Y43.28%
ROICexgc growth 5Y4.77%
ROICexc growth 3Y41%
ROICexc growth 5Y11.99%
OM growth 3Y21.43%
OM growth 5Y8.6%
PM growth 3Y251.6%
PM growth 5Y18.9%
GM growth 3Y3.31%
GM growth 5Y0.47%
F-Score7
Asset Turnover0.51
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.61 | ||
| Debt/FCF | 3.41 | ||
| Debt/EBITDA | 1.34 | ||
| Cap/Depr | 84.97% | ||
| Cap/Sales | 9.59% | ||
| Interest Coverage | 10.83 | ||
| Cash Conversion | 73.11% | ||
| Profit Quality | 101.79% | ||
| Current Ratio | 0.88 | ||
| Quick Ratio | 0.69 | ||
| Altman-Z | 3.49 |
F-Score7
WACC8.8%
ROIC/WACC1.64
Cap/Depr(3y)61.87%
Cap/Depr(5y)60.41%
Cap/Sales(3y)7.51%
Cap/Sales(5y)7.64%
Profit Quality(3y)144.6%
Profit Quality(5y)772.45%
High Growth Momentum
Growth
EPS 1Y (TTM)20.61%
EPS 3Y15.85%
EPS 5Y18.59%
EPS Q2Q%14.42%
EPS Next Y11.95%
EPS Next 2Y12.55%
EPS Next 3Y12.2%
EPS Next 5Y12.45%
Revenue 1Y (TTM)13.52%
Revenue growth 3Y13.06%
Revenue growth 5Y17.27%
Sales Q2Q%11.99%
Revenue Next Year10.2%
Revenue Next 2Y8.11%
Revenue Next 3Y7.34%
Revenue Next 5Y7.17%
EBIT growth 1Y26.07%
EBIT growth 3Y37.28%
EBIT growth 5Y27.35%
EBIT Next Year32.31%
EBIT Next 3Y16.96%
EBIT Next 5Y13.16%
FCF growth 1Y37.12%
FCF growth 3Y24.58%
FCF growth 5Y70.22%
OCF growth 1Y46.1%
OCF growth 3Y25.76%
OCF growth 5Y31.92%
ASTRAZENECA PLC-SPONS ADR / AZN FAQ
Can you provide the ChartMill fundamental rating for ASTRAZENECA PLC-SPONS ADR?
ChartMill assigns a fundamental rating of 6 / 10 to AZN.
What is the valuation status for AZN stock?
ChartMill assigns a valuation rating of 6 / 10 to ASTRAZENECA PLC-SPONS ADR (AZN). This can be considered as Fairly Valued.
How profitable is ASTRAZENECA PLC-SPONS ADR (AZN) stock?
ASTRAZENECA PLC-SPONS ADR (AZN) has a profitability rating of 9 / 10.
Can you provide the PE and PB ratios for AZN stock?
The Price/Earnings (PE) ratio for ASTRAZENECA PLC-SPONS ADR (AZN) is 19.98 and the Price/Book (PB) ratio is 6.21.
What is the expected EPS growth for ASTRAZENECA PLC-SPONS ADR (AZN) stock?
The Earnings per Share (EPS) of ASTRAZENECA PLC-SPONS ADR (AZN) is expected to grow by 11.95% in the next year.